HOME >> MEDICINE >> NEWS
Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL
'"/>

Contact: Robert Sebbag/Beth Waters
33-60-817-2183
Cooney Waters Group, Inc.
25-Feb-2002


Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aventis Pasteur statement HVTN decision

(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... 31, 2014 Gold Medal Wine Club ... affordable but tasteful gifts for the wine novice and enthusiasts ... Bird Gift Giving Special , which Early Bird shoppers receive ... Wine Club Gift membership. , Gift Givers must place ... special. Besides offering discounts, Gold Medal Wine Club adds more ...
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... drug combination that can trigger the self-destruct process in ... treatments, according to research that will be presented at ... Liverpool next week*. , When healthy cells are no ... in self destruction. But cancer cells swerve away from ... cells grow out of control – causing tumours to ...
(Date:10/31/2014)... 2014 FindSurrogateMother.com conveys a ... of life — building a family through surrogacy. The ... and donors with hopeful intended parents in turn generating ... It’s a collective aptitude of surrogate mothers, intended parents, ... fertility clinics that help provide these connections — and ...
Breaking Medicine News(10 mins):Health News:Advance directives can benefit patients, families, and health care system 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
(Date:10/31/2014)... , Oct. 30, 2014 Migranade, Inc. announced ... be available to the 36 million U.S. migraine sufferers ... technology that targets the actual cause of migraines and ... pain and not the source Migranade is assured to ... MIGRANADE Migraine Relief is available at http://www.migranade.com ...
(Date:10/31/2014)...  AbbVie (NYSE: ABBV ) today ... Sept. 30, 2014. "Our third-quarter ... with double-digit growth from HUMIRA and several other ... percent in the quarter excluding lipids," said Richard ...  "We exceeded our outlook for the quarter and ...
(Date:10/30/2014)... , Oct. 30, 2014 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the pharmaceutical, ... China and the United ... representative office in the Tel Aviv ... office will promote WuXi,s broad platform of integrated R&D ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2
Cached News: